A person can inject tesamorelin nightly for six months, step on the same scale each morning, watch the number refuse to move, and decide the drug did nothing. That is the most common way tesamorelin results get misread, and the misreading is written into the label: the fat this molecule removes is fat a bathroom scale does not weigh.
Here is the direct answer. In the trials that made it a drug, tesamorelin results meant roughly 15% less visceral fat over 26 weeks, a measurable cut in liver fat, and no meaningful change in body weight. The label says so in plain words: EGRIFTA SV is “not indicated for weight loss management as it has a weight neutral effect,” according to the prescribing information published on DailyMed on 31 July 2026.
So the honest version of the question “does tesamorelin work” depends entirely on what you were promised. If someone sold it to you as a weight-loss drug, the answer is no, and it was no from the start. If the goal was the fat packed around the organs, there is real trial evidence, and it is unusually specific.
Tesamorelin Results: The Fat It Moves Is the Fat You Cannot Pinch
Human fat is not one tissue. Subcutaneous fat sits under the skin and is what a caliper, a tape measure and a mirror all report. Visceral adipose tissue wraps the organs inside the abdominal wall. You cannot pinch it. You can barely feel it. It is measured by CT or MRI scan, and it is the fat most tightly linked to metabolic trouble.
Tesamorelin is a growth hormone-releasing factor analog. It tells the pituitary to release the body’s own growth hormone, which is why it behaves like a targeted demolition crew rather than a diet. The trials measured the tissue mechanically, in square centimeters on a scan, not in pounds on a floor tile.
The clearance for this molecule is narrow and worth saying out loud. EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Not for general obesity. Not for cosmetic cutting. The same label states that long-term cardiovascular safety has not been established.
The Phase 3 Numbers: 806 Patients, 15.4%, and No Change in the Belly You Can Grab
The two pivotal phase 3 trials were pooled and published by Falutz and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2010. Eight hundred and six antiretroviral-treated adults with excess abdominal fat were randomized two to one to tesamorelin 2 mg subcutaneously daily or placebo. At week 26, visceral fat fell by 24 cm² on tesamorelin and rose by 2 cm² on placebo, a treatment effect of −15.4%. Abdominal subcutaneous fat did not budge: −2 versus 2 cm², a treatment effect of −0.6%, not statistically significant.
Those two sentences are the commercial argument and the patient disappointment in one place. The scan moved. The waistband mostly did not.
A separate 404-patient trial, published by Falutz and colleagues in the Journal of Acquired Immune Deficiency Syndromes in 2010, found visceral fat down 10.9% (−21 cm²) against −0.6% on placebo at six months, with trunk fat, waist circumference and waist-to-hip ratio all improving and limb fat unchanged.
Liver Fat: The Finding the Label Did Not Promise
Visceral fat sits next to the liver, and the liver was the next question. Stanley and colleagues ran a 50-patient double-blind trial at Massachusetts General Hospital, published in JAMA in 2014. Over six months, visceral fat treatment effect was −42 cm² (95% CI, −71 to −14; P = .005) and liver fat fell by a net −2.9% on magnetic resonance spectroscopy (P = .003). That was a small mechanistic study, and it pointed somewhere.
The follow-up was definitive enough to matter. Stanley and colleagues published a 61-patient, 12-month, double-blind, multicentre trial in Lancet HIV in 2019, enrolling people with HIV and a hepatic fat fraction of 5% or more. Tesamorelin beat placebo on the primary endpoint: an absolute hepatic fat fraction reduction of −4.1 percentage points (95% CI, −7.6 to −0.7; P = .018), which the authors described as a relative reduction of about 37%.
In 2024, Russo and colleagues re-analyzed 38 participants from that trial who were taking integrase inhibitors, the modern backbone of HIV therapy, and published in AIDS. Visceral fat fell 25 cm² against a 14 cm² rise on placebo (P = .001), hepatic fat fell 4.2% against 0.5% (P = .01). The phase 3 trials were run before those drugs existed, so this was the first dedicated look at the population a clinic would see today.
The 2026 Meta-Analysis: Five Trials, and the Number That Is Missing
Badran and colleagues pooled five randomized trials in Obesity Research and Clinical Practice in 2026. Visceral fat: mean difference −27.71 cm² (95% CI, −38.37 to −17.06). Trunk fat: −1.18 kg. Waist circumference: −1.61 cm. Hepatic fat: −4.28%. Lean body mass: +1.42 kg.
Then the sentence that matters most. There was no significant reduction in subcutaneous fat and no significant reduction in BMI. Not a small effect. Not a trend. No significant change.
A second 2026 review, by Ditta and colleagues in the Journal of the International Association of Providers of AIDS Care, combined four trials covering 909 people and reached the same place: less abdominal fat, smaller waist, less trunk fat, slightly more lean mass, modest cholesterol improvement, and side effects to weigh.
Both review teams landed in the same place. If a marketing page shows you a tesamorelin before-and-after and the only before-and-after is a body photo, the photo is not the result the studies measured.
What Tesamorelin Results Do Not Include
All of the efficacy trials above enrolled adults with HIV and excess abdominal fat. That is the population the evidence describes, and there is no large trial of tesamorelin in people without HIV. One 12-week safety study in 53 patients with type 2 diabetes, published by Clemmons and colleagues in PLoS One in 2017, found no change in insulin response or glycemic control, which is reassuring about short-term glucose handling and is not evidence of fat loss in that population.
The label also carries the costs. Tesamorelin raises IGF-1, and the effects of prolonged elevation are unknown, so the label directs monitoring of IGF-1 during therapy. Fluid retention, joint pain, peripheral edema and carpal tunnel syndrome appear among the most commonly reported adverse reactions at rates above 5%. Glucose intolerance or diabetes may develop, so glucose is evaluated before and during treatment. Active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and known hypersensitivity are contraindications. The label directs 1.4 mg of EGRIFTA SV subcutaneously once daily for that formulation; the trials used 2 mg of the earlier formulation. Neither figure is a plan , dosing belongs to the prescriber holding the labs.
Here is the part that should end the argument for anyone shopping a vial online. EGRIFTA is an FDA-approved prescription product for HIV-associated lipodystrophy. A compounded tesamorelin vial is not that product, is not FDA-approved, and does not carry that label’s manufacturing, potency or sterility guarantees. Tesamorelin does not appear on the FDA’s list of bulk drug substances that may present significant safety risks as of 28 October 2026, but absence from a warning list has never been approval.
How to Read a Tesamorelin Result Someone Shows You
Ask what was measured. If the answer is a number on a scale or a photograph, the number is about a different tissue than the one the trials moved. If the answer is visceral fat on CT or MRI, ask in whom, because the evidence is in adults with HIV and lipodystrophy.
Ask whether IGF-1 and glucose were checked before and during treatment. A clinic selling this molecule without those labs is selling a growth hormone secretagogue to someone it has not measured.
And ask what happens at month six. The label asks prescribers to reconsider continuing in patients who have not had a reduction in visceral adipose tissue. That is a stop rule, written by the manufacturer, and it is the most useful sentence in the whole document. If you are trying to work out which clinics will run those checks, our clinic directory is where the licensed ones are listed, and the compounds hub explains what each peptide is before anyone injects it.
Frequently asked questions
Does tesamorelin work for weight loss?
No. The FDA label for EGRIFTA SV states it is not indicated for weight loss management and has a weight-neutral effect, and the 2026 five-trial meta-analysis found no significant reduction in BMI.
How much visceral fat does tesamorelin remove?
In the pooled phase 3 trials the treatment effect was −15.4% visceral fat at 26 weeks. The 2026 meta-analysis of five trials reported a mean difference of −27.71 cm².
How long before tesamorelin results show up?
The pivotal trials measured the primary endpoint at 26 weeks, and the liver fat trial ran 12 months. No one has published a reliable early response window, and a scale reading at week four tells you nothing about visceral fat.
Does tesamorelin reduce liver fat?
Yes, in people with HIV. The 2019 Lancet HIV trial found an absolute hepatic fat fraction reduction of 4.1 percentage points against placebo at 12 months, about 37% relative, in people who started with at least 5% liver fat.
Is compounded tesamorelin the same as Egrifta?
No. Egrifta is an FDA-approved product for HIV-associated lipodystrophy. A compounded vial is not FDA-approved, is not interchangeable by default, and does not carry the approved label’s monitoring requirements, which is precisely the part that matters.
Can you take tesamorelin without HIV?
The efficacy data comes from adults with HIV and excess abdominal fat. There is no large trial in people without HIV, so any claim about results in that population is extrapolation rather than evidence.
What are the main risks of tesamorelin?
Elevated IGF-1 with unknown long-term effects, fluid retention, joint and muscle pain, carpal tunnel syndrome, glucose intolerance or new diabetes, injection site reactions, and an increased risk of neoplasms in a population already at higher baseline risk. The label directs IGF-1 and glucose monitoring.
Sources
- EGRIFTA SV (tesamorelin) prescribing information, Theratechnologies, DailyMed, published 31 July 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Falutz J, Mamputu JC, Potvin D, Moyle G, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID 20554713. pubmed.ncbi.nlm.nih.gov/20554713
- Falutz J, Potvin D, Mamputu JC, Assaad H, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: randomized placebo-controlled trial with safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PMID 20101189. pubmed.ncbi.nlm.nih.gov/20101189
- Stanley TL, Feldpausch MN, Oh J, Branch KL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID 25038357. pubmed.ncbi.nlm.nih.gov/25038357
- Stanley TL, Fourman LT, Feldpausch MN, Purdy J, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31611038. pubmed.ncbi.nlm.nih.gov/31611038
- Russo SC, Ockene MW, Arpante AK, Johnson JE, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PMID 38905488. pubmed.ncbi.nlm.nih.gov/38905488
- Badran AS, Helal A, Shata KS, Ayesh H, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PMID 41545261. pubmed.ncbi.nlm.nih.gov/41545261
- Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, et al. Efficacy and safety of tesamorelin in people living with HIV with lipodystrophy: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2026;25. PMID 42538058. pubmed.ncbi.nlm.nih.gov/42538058
- Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PMID 28617838. pubmed.ncbi.nlm.nih.gov/28617838
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Retrieved 28 October 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
This page is educational information, not medical advice, a diagnosis, or a treatment recommendation. It does not recommend any peptide, medication, pharmacy, clinic, or treatment plan, and it makes no claim that any unapproved substance is safe or effective. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed. Doses vary, and the decision about a prescription belongs to a licensed clinician who knows your history. Talk to your prescriber about your own situation, and see our full medical disclaimer.